88040-23-7
Chemical Structure
Cefepime
Synonym(s): BMY-28142
- CAS No.: 88040-23-7
- Formula:C19H24N6O5S2
- Molecular Weight:480.56
IUPAC Name: (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((1-methylpyrrolidin-1-ium-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
InChIKey: HVFLCNVBZFFHBT-ZKDACBOMSA-N
SMILES: C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1
Biological Activity: Cefepime (BMY-28142) is a broad-spectrum, blood-brain barrier-permeable cephalosporin antibiotic with hPON1 inhibitory activity, with an IC50 of 21.115 mM and a Ki of 35.092 mM. Cefepime inhibits hPON1 via a non-competitive mechanism and blocks GABAA receptors. Cefepime exhibits high affinity for PBPs, inhibits the growth of both Gram-positive and Gram-negative bacteria, and does not induce the production of β-lactamases[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cefepime | 99.86% | Cefepime (BMY-28142) is a broad-spectrum, blood-brain barrier-permeable cephalosporin antibiotic with hPON1 inhibitory activity, with an IC50 of 21.115 mM and a Ki of 35.092 mM. Cefepime inhibits hPON1 via a non-competitive mechanism and blocks GABAA receptors. Cefepime exhibits high affinity for PBPs, inhibits the growth of both Gram-positive and Gram-negative bacteria, and does not induce the production of β-lactamases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefepime (Standard) | 99.94% | Cefepime (Standard) (BMY-28142 (Standard)) is the analytical standard of Cefepime (HY-B0692). This product is intended for research and analytical applications. Cefepime (BMY-28142) is a broad-spectrum, blood-brain barrier-permeable cephalosporin antibiotic with hPON1 inhibitory activity, with an IC50 of 21.115 mM and a Ki of 35.092 mM. Cefepime inhibits hPON1 via a non-competitive mechanism and blocks GABAA receptors. Cefepime exhibits high affinity for PBPs, inhibits the growth of both Gram-positive and Gram-negative bacteria, and does not induce the production of β-lactamases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.93
HY-B0692ACefepime chloride -
Similarity Score 0.92
HY-108877Cefepime hydrochloride -
Similarity Score 0.91
HY-B0616RCefepime Dihydrochloride Monohydrate (Standard) -
Similarity Score 0.75
HY-126818Desfuroylceftiofur -
Similarity Score 0.75
HY-126129Desacetylcefotaxime -
Similarity Score 0.75
HY-A0251Cefpodoxime -
Similarity Score 0.75
HY-A0111BCefetamet hydrochloride -
Similarity Score 0.75
HY-A0111RCefetamet (Standard) -
Similarity Score 0.73
HY-A0111ACefetamet sodium -
Explore the MedChemAI to find more analogs
References
- [1]. Türkeş C, et al. Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem. 2015;30(4):622-628. [Content Brief]
- [2]. Pais GM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022;61(7):929-953. [Content Brief]
- [3]. Tanaka A, et al. Convulsive liability of cefepime and meropenem in normal and corneal kindled mice. Antimicrob Agents Chemother. 2014;58(8):4380-4383. [Content Brief]
- [4]. Neu HC, et al. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17(4):441-452. [Content Brief]
- [5]. Smith HG, et al. Structural basis of Pseudomonas aeruginosa penicillin binding protein 3 inhibition by the siderophore-antibiotic cefiderocol. Chem Sci. 2024 Sep 18;15(41):16928-16937.
